Pharmaceutical Deal Dynamics: AbbVie and Allergan's $63 Billion Acquisition

Boeing faces another setback in its attempt to get the 737 Max back in the air, activist investor Carl Icahn is preparing a campaign to oust four of Occidental Petroleum’s board members and private equity deal-making hits its highest level since the lead-up to the global financial crisis. Plus, the FT’s corporate finance and deals editor, Arash Massoudi, explains what led to AbbVie’s $63bn acquisition of Botox-maker Allergan.

---

Hosted on Acast. See acast.com/privacy for more information.